Targeting IKK and NF-κB for Therapy

J K Durand; A S Baldwin

doi:10.1016/bs.apcsb.2016.11.006

Targeting IKK and NF-κB for Therapy

Adv Protein Chem Struct Biol. 2017:107:77-115. doi: 10.1016/bs.apcsb.2016.11.006. Epub 2017 Jan 11.

Authors

J K Durand¹, A S Baldwin²

Affiliations

¹ Curriculum in Genetics and Molecular Biology, University of North Carolina, Chapel Hill, NC, United States; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, United States.
² Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, United States. Electronic address: [email protected].

PMID: 28215229
DOI: 10.1016/bs.apcsb.2016.11.006

Abstract

In addition to regulating immune responses, the NF-κB family of transcription factors also promotes cellular proliferation and survival. NF-κB and its activating kinase, IKK, have become appealing therapeutic targets because of their critical roles in the progression of many diseases including chronic inflammation and cancer. Here, we discuss the conditions that lead to pathway activation, the effects of constitutive activation, and some of the strategies used to inhibit NF-κB signaling.

Keywords: Cancer; IKK; Inflammation; NF-κB; Therapeutic targets; Transcription factor.

Publication types

Review

MeSH terms

Cell Proliferation
Cell Survival
Clinical Trials as Topic
Drug Resistance, Neoplasm
Humans
I-kappa B Kinase / antagonists & inhibitors*
Inflammation / drug therapy
Inflammation / metabolism
NF-kappa B / antagonists & inhibitors*
Signal Transduction

Substances

NF-kappa B
I-kappa B Kinase